PALMER, James (UNIVERSITY HOSPITALS PLYMOUTH NHS TRUST)

From:	PALMER, James (UNIVERSITY HOSPITALS PLYMOUTH NHS TRUST)
Sent:	11 July 2022 16:30
То:	KESSEL, Anthony (NHS ENGLAND – X24); (NHS
	ENGLAND – X24);
Cc:	; Taylor, Charlotte;
Subject:	RE: APPG consultation on Evusheld
Jubject.	NE. 711 G CONSUMMENT ON EVASITION
We won't be planning to c	contribute to from NHS England.
Prof. James D Palmer National Medical Director	Specialised Services NHS England
to Medical Direct	or
From: 11 July 2022 12:50	
Sent: 11 July 2022 12:50 To: PALMER James (LINI)	/ERSITY HOSPITALS PLYMOUTH NHS TRUST) >; KESSEL, Anthony
(NHS ENGLAND – X24)	>; (NHS ENGLAND – X24)
(MIS ENGLAND X24)	(WIS ENGLAND X24)
Cc:	Taylor,
Charlotte	
	>
Subject: APPG consultation	on on Evusheld
Hi James, Anth	
	rty Parliamentary Group has launched a consultation to obtain 'clinical consensus' on rulnerable groups, including use of Evusheld. It's supported by the ser Programme.
Consultation launch: Clini	cal consensus statement on protective measures for vulnerable groups: Appg
Vulnerablegroups (appg-\	
Is this process something	NHS England, NICE or any of the agencies would contribute to?
	ceived advice on Evusheld, we plan to write to parliamentarians and could include the note). But wanted to check in with you on any clinical engagement your side might lead
Thank you,	
Local Association in	
8	
Department	- Antivirals and Therapeutics Taskforce
of Health &	Department of Health and Social Care, 39 Victoria Street, SW1H 0EU
Social Care	E:

This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.